The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching US$9.39 billion ...

The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching US$9.39 billion in 2024 and an impressive US$13.33 billion by 2029.

The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, ...

About KAMRAB® KAMRAB is a human rabies immune globulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after ...

Shingles vaccine industry is projected to witness a CAGR of 10.1% during the period 2025-2034. This growth can be attributed ...

Researchers at Baylor College of Medicine and collaborating institutions have improved our understanding of how rotavirus, ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Live-attenuated respiratory syncytial virus (RSV) vaccines are highly immunogenic among HIV-exposed uninfected (HEU) pediatric patients, according to results of a study published in Open Forum ...

Manufacturers are investing in key recombinant vaccines and improving product pipelines, driving growth in the market.

Live attenuated vaccines are antigenic substances composed of a viable (living) pathogen, such as a virus or bacterium. The pathogen is altered so that it is less virulent or avirulent (attenuated).